Melatonin Osteoporosis Prevention Study (MOPS)
|First Received Date ICMJE||June 28, 2010|
|Last Updated Date||March 9, 2012|
|Start Date ICMJE||September 2008|
|Primary Completion Date||July 2010 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
|Original Primary Outcome Measures ICMJE
||Bone density and bone turnover markers, bone-specific alkaline phosphatase (BAP) and type 1 collagen cross-linked N-telopeptide (NTX) will be measured to assess osteoblast and osteoclast activity, respectively. [ Time Frame: Heel measurements will be made at baseline and each month. Bone marker turnover will be measured at baseline and every other month ]
Bone density will be measured on the heel of the foot using the Achilles machine with 92% accuracy using this method. All of these markers will be assessed in the blood and by ELISA using kits (BAP=Ostace, NTX = Osteomark) according to the manufacturer's instructions.
|Change History||Complete list of historical versions of study NCT01152580 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE
||Questionnaires geared to measure compliance with the treatment program, self-perceived quality of life as measured by the MENQOL and sleep habits as measured by the Pittsburgh Sleep Questionnaire. [ Time Frame: These questionnaires will be assessed at baseline and after 6 months ]
All of the questionnaires are validated surveys to measure menopause quality of life (MENQOL) and sleep (Pittsburgh Sleep Questionnaire, a validated tool that assesses the quality and quantity of sleep and sleep disorders). The study subjects will also maintain daily diaries. Also, during the 6-month intervention period, the nurse coordinator will call each subject monthly, to answer any questions or concerns, and to promote adherence to study procedures.
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Melatonin Osteoporosis Prevention Study|
|Official Title ICMJE||Assessing the Efficacy of Melatonin on Bone Health in Peri-menopausal Women|
|Brief Summary||Osteoporosis is one of the most common skeletal disorders. Today in the United States, 10 million individuals have osteoporosis and 34 million more have low bone mass or osteopenia, which places them at an increased risk of some day developing osteoporosis. Of the people affected by this problem, 68% are women.The current thinking on the development of osteoporosis is that the changes in bone turnover that occur with aging play a major factor. Many modalities of treatment are used to prevent the bone loss and increased fracture risk associated with osteoporosis and osteopenia. Melatonin supplementation may be another treatment modality that lowers risk of hip fracture in perimenopausal women. Melatonin can remodel bone in animal models and in culture. Melatonin works through melatonin receptors to form osteoblasts from human mesenchymal stem cells and has been shown to inhibit osteoclast activity in rodents. Melatonin levels have been correlated with modulating bone markers; low nocturnal levels of melatonin correlate with in an increase in bone marker metabolism and osteoporosis. It is been shown that women who have worked night-shifts for greater than 20 years have increased risk for wrist and hip fractures. Night-shift workers have lower nocturnal melatonin levels than people who do not work the night-shift. The addition of exogenous melatonin suppresses bone marker metabolism. In human stem cells taken from bone marrow, melatonin increases the activity of bone-forming cells called osteoblasts. It is hypothesized that melatonin will improve bone health, menopausal quality of life and sleep compared to placebo in perimenopausal women. In particular, the investigators expect perimenopausal women taking melatonin to show an improvement in overall bone health as revealed by a reduction in bone marker turnover since bone resorption increases more so than bone absorption in this population compared to those women taking placebo. We also expect that perimenopausal women taking melatonin to have better control over their menopausal symptoms, better quality of life and less sleep disturbances when compared to their placebo controls since melatonin is known to modulate estrogen levels in the body and regulate sleep. The data from these studies may provide novel and alternative uses for melatonin; in particular its use for the prevention and/or treatment of osteoporosis.|
BACKGROUND AND SIGNIFICANCE Osteoporosis is one of the most common skeletal disorders. Today in the United States, 10 million individuals have osteoporosis and 34 million more have low bone mass or osteopenia, which places them at an increased risk of some day developing osteoporosis. Of the people affected by this problem, 68% are women. Osteoporosis is characterized by low bone mass and microarchitectural disruption, such that fewer, thinner bony spicules are present leading to less structural support. These hallmark features of osteoporosis lead to increased skeletal fragility and an increased fracture risk. Hip fracture specifically has been shown to be a major problem leading to increased morbidity and mortality. In addition osteoporotic fractures are responsible for a large portion of health care spending. In 1995 $13.8 billion in health care expenditures were attributable to osteoporotic fractures. Because the health of older adults often deteriorates after hip fracture, efforts to prevent fracture by treating and preventing osteoporosis are critical to reducing this common cause of morbidity, mortality and health service utilization.
The current thinking on the development of osteoporosis is that the changes in bone turnover that occur with aging play a major factor. One study which measured markers of bone formation, such as osteocalcin (OC), and markers of bone resorption, such as type I collagen cross-linked N-telopeptide (NTX), showed that rates of bone formation and resorption are high in elderly women. However, bone resorption increases more so than bone formation leading resorption to be the major determinant of bone mass. These biochemical markers of bone formation and resorption may play an important role in monitoring therapy. In a recent review that examined clinical studies in which bone turnover markers were measured after beginning treatment with a bisphosphonate, the data showed that suppression of bone turnover markers occurred after as little as three months of therapy.[6,7] This suppression in bone turnover markers was also associated with reduction in risk for fracture.[6,7] Although dual X-ray absorptiometry (DXA) is the gold standard for diagnosis of osteoporosis and osteopenia, recent reports are showing that DXA may not be the best method for measuring bone health. For example, bone fractures routinely occur despite modest bone mineral density levels and no significant reduction in the risk of fracture occurs in patients taking one of the two standard medications, one that significantly increases bone mineral density and the other that moderately increases it. Thus, it is currently thought that bone quality may not be clinically assessed by measures other than the determination of bone metabolism with biochemical markers of bone turnover because these markers measure "living" bone cells. Many modalities of treatment are used to prevent the bone loss and increased fracture risk associated with osteoporosis and osteopenia. One method involves use of calcium and vitamin D supplementation such that total calcium intake is approximately 1500 mg/day. Calcium and vitamin D supplementation may increase bone mineral density to a small extent, but not nearly to the same degree as is seen with other treatment modalities. Therefore, it is often combined with another treatment method for better efficacy. Bisphosphonates are being used more and more often in postmenopausal women. These antiresorptive agents have been shown to prevent bone loss and reduce the incidence of vertebral and nonvertebral fractures. Calcitonin has been shown to decrease vertebral fractures, increase bone mineral density at the lumbar spine and inhibit bone turnover.
Melatonin supplementation may be another treatment modality that lowers risk of hip fracture in perimenopausal women. Melatonin can remodel bone in animal models and in culture. Melatonin works through melatonin receptors to form osteoblasts from human mesenchymal stem cells and has been shown to inhibit osteoclast activity in rodents. Melatonin levels have been correlated with modulating bone markers whereby low nocturnal levels of melatonin correlate with in an increase in bone marker metabolism and osteoporosis. The addition of exogenous melatonin suppresses bone marker metabolism. Work from my laboratory reveals that application of melatonin to human bone stem cells grown in culture enhances alkaline phosphatase activity by 50% and calcium deposition by 10-fold.
HYPOTHESIS AND SPECIFIC AIMS We hypothesize that melatonin will improve bone health, menopausal quality of life and sleep compared to placebo in perimenopausal women.
PRIMARY ENDPOINTS: The primary outcome variables are bone turnover marker status, and melatonin levels as measured in blood and bone density as measured by the Achilles method.
RESEARCH PLAN This study is a longitudinal, cohort trial of 20 subjects who are perimenopausal and aged 45 years old or greater who have new onset of irregular menses not due to other known causes such as polycystic ovaries or hypothyroidism. Perimenopause is defined as the time between the onset of menstrual irregularity and menopause; there is no lab test that is diagnostic of perimenopause. Thus, the investigators will include women who, according to their age, are likely to be perimenopausal (age 45 or greater) and who have symptoms of perimenopause (irregular menses). Once a cohort of 20 subjects is recruited, the investigators will randomize volunteers using a computer-generated blocked randomization scheme. Five study subjects will receive placebo and 15 study subjects will receive melatonin, 3 mg). The women enrolled in the study will be asked to take their treatments by mouth at bedtime each day for 6 months to coincide with the nocturnal surge in melatonin each day. This dose of melatonin has been chosen because 3 mg melatonin is commonly used to induce phase-shifts in circadian rhythms in people. Seeing that this is one of our secondary endpoints, this dose is appropriate. Regarding melatonin's effects on bone, there is nothing known about its efficacy on forming bone in women. Therefore, the dose of melatonin was chosen based on the reported literature using pre-clinical or in vitro culture models that showed positive effects on bone formation. These reports show variable effects of melatonin ranging from 400 pM in rat , to 5 mg melatonin in mouse (unpublished data) to 50 nM on human mesenchymal stem cells grown in culture.[12,16] The bioavailability of melatonin is 17% in females taking 250 mcg melatonin po. Thus, a 3 mg dose of melatonin taken by mouth would result in a nocturnal exogenous level of 2.19 mM. The terminal half-life of melatonin is about 41 minutes in females , however, accumulation of melatonin in the bone marrow occurs . Therefore, these data suggest that our 3 mg dose is appropriate for these studies.
PLANS FOR ASSESSMENT AND STUDY OUTCOMES Our primary outcome will be the levels of bone turnover markers, OC and NTX, bone density and melatonin taken at baseline and then after 6 months of treatment. The change in bone turnover marker levels will be compared between those taking melatonin and those taking placebo. Baseline levels of OC and NTX will be calculated. For this study the investigators will also visually inspect the data in order to perform descriptive analyses of the demographic characteristics of our population, such as age, and weight. We will explore characteristics of any individuals who have a significant improvement in their bone turnover markers, such as compliance with the treatment, diet, and lifestyle as determined by the diary. We will also make note of characteristics such as current or past cigarette smoking and alcohol and caffeine consumption as individuals with these risk factors may show less improvement in their bone turnover markers. We will use intention to treat as our primary analysis. We will attempt to minimize missing data with careful follow-up of subjects, maintaining consistent contact with them over the study period, and remunerating them for their inconvenience. If a subject drops out of the study, the investigators will still attempt to obtain their follow up studies.
Expected Outcomes.We expect perimenopausal women taking melatonin to show an improvement in overall bone health as revealed by an increase in bone density, an increase in OC and a decrease in NTX levels when compared to those women taking placebo. We also expect those taking melatonin to have better control over their menopausal symptoms, better quality of life and less sleep disturbances compared to their placebo controls. The potential benefits of participating in this study include the possibility of decreasing bone turnover and reducing fracture risk as well as improve sleep regardless, a condition much affected in this population of women. The data from these studies may provide novel and alternative uses for melatonin for the prevention of osteoporosis and provide women with more options to manage diseases associated with menopause.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 1|
|Study Design ICMJE||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||July 2010|
|Primary Completion Date||July 2010 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||45 Years to 54 Years (Adult)|
|Accepts Healthy Volunteers||Yes|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT01152580|
|Other Study ID Numbers ICMJE||07-88|
|Has Data Monitoring Committee||No|
|U.S. FDA-regulated Product||Not Provided|
|Plan to Share Data||Not Provided|
|IPD Description||Not Provided|
|Responsible Party||Duquesne University|
|Study Sponsor ICMJE||Duquesne University|
|Collaborators ICMJE||Not Provided|
|Information Provided By||Duquesne University|
|Verification Date||March 2012|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP